Elicera Therapeutics develops new cancer treatment with help of advanced cell lab in Flemingsberg
Uppsala-based Elicera Therapeutics is using the Pre-GMP core facility at Vecura in Flemingsberg as a first step in a study aimed at creating a new treatment for lymph node cancer.
The pre-GMP lab at Campus Flemingsberg makes it possible to use a new method to automate the process of genetically modifying cells for research studies.
“The facility allows us to benefit from a completely closed and automated system that reduces the workload for staff and further ensures quality,” says Magnus Essand, Research Director at Elicera.
In the Pre-GMP lab, the process can be developed and fine-tuned while staff at Vecura receive training in the new methods.
Activating the immune system
The establishment of Elicera Therapeutics was based on research conducted at Uppsala University with the aim of using modified cells – CAR-T cells – to develop new cancer treatments. Cells taken from patients develop the ability to activate the body’s own immune system in the fight against cancer.
The goal of the current study is to identify a treatment for patients with Non-Hodgkin’s lymphoma, a form of lymph node cancer.
“There are currently two approved treatments for the disease, but they don’t work for all patients. We hope that our treatment can also be used by these patients and prevent recurrence,” says Essand, adding: “We hope to develop a curative treatment for these patients.”
Elicera Therapeutics recently received a grant from the European Innovation Council (EIC) to help them grow further. In the future, there are plans to use the company’s findings to develop treatments for patients with brain cancer.
Read more on the Elicera Therapeutics homepage at: elicera.com.
Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science
Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund (ERDF) and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.
BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development
As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.
Sally Sow and Turn UP: Winners of the Flemingsberg Science Award IDEA 2024
The music world can be a challenging place, both for organizers trying to reach their audience and for music lovers searching for events that suit their taste. Sally Sow, the winner of the Flemingsberg Science Award IDEA 2024, has developed Turn Up, a platform that simplifies organizing, discovering, and participating in local music events. With a focus on inclusion and accessibility, she aims to create a music scene where everyone feels welcome.
KTH’s Technical Preparatory Year Moves to Flemingsberg – Student Numbers Expected to Double in Autumn 2025
In the autumn of 2025, KTH will relocate its Technical Preparatory Year spots from Södertälje to Flemingsberg, resulting in a significant increase in student numbers at Campus Flemingsberg. By nearly doubling available seats and introducing a new learning center model in collaboration with 3 municipalities, KTH aims to meet the growing demand for technical education in the region.
